IWC
SVA

Integrated Wealth Concepts’s Sinovac Biotech, Ltd SVA Stock Holding History

Integrated Wealth Concepts’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+366
New – ﹤0.01% 5921

Other funds holding SVA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
HI
Horizon Investments Charlotte, North Carolina $9.13B AUM 34.49% 1-Year Est. Return

Integrated Wealth Concepts's SVA Position: Q2 2026 in Review

Integrated Wealth Concepts opened a new position in Sinovac Biotech, Ltd (SVA) in Q2 2026: 366 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #5921 among its holdings.

29 funds tracked by Wall St. Rank hold SVA as of Q2 2026.

  • Integrated Wealth Concepts held 366 shares of Sinovac Biotech, Ltd worth $0 as of Q2 2026.
  • Sinovac Biotech, Ltd was a new Integrated Wealth Concepts position in Q2 2026.
  • Sinovac Biotech, Ltd made up ﹤0.01% of Integrated Wealth Concepts's portfolio in Q2 2026, its #5921 holding.
  • 29 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2026.

Based on Integrated Wealth Concepts's 13F filing for Q2 2026, filed 12 Aug 2026.